Beijing SL Pharmaceutical Co Ltd
002038
Company Profile
Business description
Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.
Contact
No.69 Fu shi Road
No.1 Building, Bitongyuan
Haidian district
Beijing100049
CHNT: +86 1088627630
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
901
Stocks News & Analysis
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks
ASX data center player expands pipeline but questions remain
Questions surround Australia’s largest data center developer and its growing pipeline.
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 77.80 | 0.88% |
| CAC 40 | 8,183.34 | 5.53 | -0.07% |
| DAX 40 | 25,104.70 | 12.45 | 0.05% |
| Dow JONES (US) | 51,038.88 | 369.91 | 0.73% |
| FTSE 100 | 10,409.28 | 16.68 | -0.16% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 27,020.32 | 102.85 | 0.38% |
| Nikkei 225 | 66,329.50 | 1,636.38 | 2.53% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,590.21 | 26.58 | 0.35% |
| S&P/ASX 200 | 8,731.70 | 73.10 | 0.84% |
| SSE Composite Index | 4,068.57 | 30.07 | -0.73% |